15.35
-0.18(-1.16%)
Currency In USD
| Previous Close | 15.53 |
| Open | 15.33 |
| Day High | 15.84 |
| Day Low | 14.97 |
| 52-Week High | 16.81 |
| 52-Week Low | 8.26 |
| Volume | 1.25M |
| Average Volume | 1.09M |
| Market Cap | 1.31B |
| PE | -9.25 |
| EPS | -1.66 |
| Moving Average 50 Days | 14.39 |
| Moving Average 200 Days | 12.33 |
| Change | -0.18 |
If you invested $1000 in Liquidia Corporation (LQDA) since IPO date, it would be worth $1,382.88 as of May 09, 2025 at a share price of $15.35. Whereas If you bought $1000 worth of Liquidia Corporation (LQDA) shares 5 years ago, it would be worth $2,065.95 as of May 09, 2025 at a share price of $15.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference
GlobeNewswire Inc.
May 06, 2025 12:00 PM GMT
MORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company’s Chief Financial
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia
GlobeNewswire Inc.
May 02, 2025 9:28 PM GMT
Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIAFDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025 MORRISVILLE, N.C., May 02, 2025
Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire Inc.
May 01, 2025 12:00 PM GMT
MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quart